Enovis (NYSE:ENOV) Insider Oliver Engert Buys 1,000 Shares of Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert bought 1,000 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were bought at an average price of $23.00 per share, with a total value of $23,000.00. Following the completion of the transaction, the insider owned 50,640 shares in the company, valued at approximately $1,164,720. This trade represents a 2.01% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Oliver Engert also recently made the following trade(s):

• On Monday, June 1st, Oliver Engert bought 1,000 shares of Enovis stock. The shares were bought at an average price of $22.22 per share, with a total value of $22,220.00.
• On Friday, March 13th, Oliver Engert bought 1,000 shares of Enovis stock. The shares were bought at an average price of $23.74 per share, with a total value of $23,740.00.

Enovis Stock Performance

NYSE:ENOV opened at $21.21 on Friday. The stock has a fifty day moving average price of $24.07 and a 200-day moving average price of $24.63. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -1.07 and a beta of 1.38. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. Enovis Corporation has a fifty-two week low of $20.55 and a fifty-two week high of $36.82.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The firm had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The company’s revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts anticipate that Enovis Corporation will post 3.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Enovis

A number of institutional investors and hedge funds have recently bought and sold shares of ENOV. Rubric Capital Management LP acquired a new position in Enovis in the 3rd quarter worth about $83,435,000. Paradigm Capital Management Inc. NY increased its holdings in Enovis by 70.2% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after purchasing an additional 732,917 shares in the last quarter. AQR Capital Management LLC increased its holdings in Enovis by 682.6% in the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock worth $15,627,000 after purchasing an additional 434,646 shares in the last quarter. Front Street Capital Management Inc. increased its holdings in Enovis by 106.1% in the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock worth $16,973,000 after purchasing an additional 384,124 shares in the last quarter. Finally, Quantinno Capital Management LP increased its holdings in Enovis by 130.8% in the 1st quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock worth $13,752,000 after purchasing an additional 342,556 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ENOV. William Blair began coverage on Enovis in a research report on Friday, April 17th. They set an “outperform” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Enovis in a research report on Friday, April 10th. Zacks Research downgraded Enovis from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 1st. Wells Fargo & Company dropped their price objective on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Finally, Needham & Company LLC upped their price objective on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $44.50.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.